Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MYLK | Q15746 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | GMNN | O75496 | 2/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.73 |
| ▸ | PRKACA | P17612 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351112 | 1.00 | ROCK1 (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL30237215 | 0.99 | LMNA (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL29651499 | 0.99 | LMNA (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL3691324 | 0.99 | LMNA (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL1981350 | 0.97 | ROCK1 (0.95) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| SCHEMBL2869228 | 0.85 | CYP3A4 (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydroxyfasudil SCHEMBL123699 | 0.84 | ROCK2 (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydroxyfasudil SCHEMBL29395466 | 0.84 | ROCK2 (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| SCHEMBL16613226 | 0.84 | KMT2A (0.74) | ROCK1CYP3A4CYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL1848494 | 0.84 | MAPK1 (1.00) | ROCK1CYP3A4CYP2D6MYLKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| EP-3022187-A1 | METHOD FOR PRODUCING A 1-(5-HALONAPHTHALENE-1-SULFONYL)-1H-HEXAHYDRO-1,4-DIAZEPINE AND COMPOSITION COMPRISING SAME | Neuroptis Biotech (FR) | 2016-05-25 | — | — | EP | claimed |
| WO-2015007896-A1 | METHOD FOR PRODUCING A 1-(5-HALONAPHTHALENE-1-SULFONYL)-1H-HEXAHYDRO-1,4-DIAZEPINE AND COMPOSITION COMPRISING SAME | NEUROPTIS BIOTECH (FR) | 2015-01-22 | — | — | WO | claimed |
| US-8273708-B2 | Regulation of paracellular permeability of the ocular surface epithelium, corresponding to the anterior segment of the eye; modulating the opening of tight junctions of the ocular epithelium; keratitis, conjunctivitis and dry eye syndrome | NEUROPTIS BIOTECH (FR) | 2012-09-25 | — | — | US | claimed |
| US-20110223177-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2011-09-15 | — | — | US | claimed |
| EP-2323637-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | University of East Anglia (GB) | 2011-05-25 | — | — | EP | claimed |
| WO-2010029350-A1 | TREATMENT OF FIBROTIC EYE DISORDERS | UNIVERSITY OF EAST ANGLIA (GB) | 2010-03-18 | — | — | WO | claimed |
| US-7452877-B2 | Methods for treating digestive functional pathologies | RYTEK (FR) | 2008-11-18 | — | — | US | claimed |
| US-20060194769-A1 | Small molecules that reduce fungal growth | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| US-20240352418-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | MEGAKARYON CORPORATION (JP) | 2024-10-24 | — | — | US | disclosed |
| EP-4342982-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | Megakaryon Corporation (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-5561140-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530119-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0690713-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021254-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK1 4/4885CYP3A4 4737/4885CYP2D6 4664/4885 |
| US-20060194769-A1 | Small molecules that reduce fungal growth | ERG28, DPM1, CYP51A1 | ROCK1 2407/4885CYP3A4 3610/4885CYP2D6 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.